Old Web
English
Sign In
Acemap
>
authorDetail
>
Zhenzhong Xia
Zhenzhong Xia
Sun Yat-sen University
Medicine
Pathology
Cancer
programmed death
Antibody
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.
2021
Journal of Clinical Oncology
Lin Shen
Jifang Gong
Jian Zhang
Dongmei Ji
Haijun Zhong
Ying Yuan
Lei Yang
Qingyuan Zhang
Yufeng Li
Mengde Wang
Chuan Qi
Zhenzhong Xia
Lingmin Lu
John Huang
Ling Sun
Li Xu
Michael Shi
Xichun Hu
Show All
Source
Cite
Save
Citations (0)
MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients.
2020
Journal of Clinical Oncology
Xichun Hu
Jifang Gong
Dongmei Ji
Lin Shen
Yufeng Li
Mengde Wang
Yingjie Huang
Zhenzhong Xia
Lingmin Lu
John Huang
Li Xu
Jenny Jing Li
Yuntao Wan
Xueming Qian
Show All
Source
Cite
Save
Citations (0)
Analysis of the clinical and pathological characteristics of 27 cases of combined hepatocellular carcinoma and cholangiocarcinoma
2008
Clinical Oncology and Cancer Research
Zhenzhong Xia
Xiaojun Lin
Xiangming Lao
Min-Shan Chen
Show All
Source
Cite
Save
Citations (0)
1